Antifibrotic effects of sodium-glucose cotransporter 2 inhibitors in patients with heart failure
Open Access
- 6 October 2023
- journal article
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 29 (1) , 5580
Abstract
Heart failure (HF) is an urgent public health problem worldwide. A fundamental role in HF progression is played by fibrosis, which causes structural myocardial and vascular changes. In this regard, it seems relevant to search for pathogenetically justified HF therapy, aimed at slowing the myocardial fibrosis progression. The results of EMPA-REG OUTCOME study showed that glucose-lowering drugs, namely sodium-glucose cotransporter 2 (SGLT2) inhibitors, have a positive effect on HF course, reducing cardiovascular mortality and hospitalization rate of patients for decompensated HF. Large-scale studies showed the antifibrotic properties of SGLT2 inhibitors. The review article presents the results of experimental studies on the use of SGLT2 inhibitors in animals. A number of mechanisms for the implementation of the antifibrotic properties of SGLT2 inhibitors affecting the cardiovascular system have been described. It seems relevant to further study SGLT2 inhibitors in clinical trials in order to identify and correct the pathogenetic mechanisms of myocardial fibrosis.Keywords
This publication has 45 references indexed in Scilit:
- Cardiac fibrosis in myocardial infarction—from repair and remodeling to regenerationCell and tissue research, 2016
- Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trialEuropean Heart Journal, 2016
- The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 DiabetesPLOS ONE, 2016
- Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic ratsJournal of Pharmacy and Pharmacology, 2014
- NADPH oxidase-dependent redox signaling in TGF-β-mediated fibrotic responsesRedox Biology, 2014
- Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic miceEuropean Journal of Pharmacology, 2013
- Strategies for biomarker discovery in fibrotic diseaseBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2013
- The pathogenesis of cardiac fibrosisCellular and Molecular Life Sciences, 2013
- Fibroblast–myocyte connections in the heartHeart Rhythm, 2012
- Increased Na+/H+-exchange activity is the cause of increased [Na+]i and underlies disturbed calcium handling in the rabbit pressure and volume overload heart failure modelCardiovascular Research, 2003